Table 2 Univariate and multivariate analysis for progression-free survival.

From: Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

Features

n (%)

Median PFS (months)

Univariate

p value

Multivariate p value

HR (CI%)

Sex

  

0.34

  

 Female

65 (42.5)

10.2

   

 Male

88 (52.5)

12.3

   

Median age, years

58 (31–86)

 

0.91

  

 < 65

101 (66)

10.6

   

 ≥ 65

51 (33.3)

12.0

   

ECOG performance status

  

0.07

  

 0

82 (53.6)

12

   

 1

60 (39.2)

10.6

   

 2

10 (6.5)

10.3

   

Initial disease stage

  

p < 0.001

p < 0.001

8 (3.2–19.8)

 Locally advanced

27 (17.6)

22.2

   

 Metastatic

126 (82.4)

10

   

Curative surgery

  

p < 0.001

0.017

2.66(1.19–5.96)

 Present

38 (24.8)

23.4

   

 Absent

115 (75.2)

9.6

   

Site of metastasis

     

 Liver

68 (44.4)

10.4

0.48

  

 Peritoneum

68 (44.4)

12.9

0.15

  

 Distant lymph nodes

49 (32)

10.5

0.62

  

 Lung

24 (15.7)

11

0.03

0.01

0.47 (0.27–0.84)

 Bone

20 (13.1)

10.4

0.056

  

 Brain

2 (1.3)

2

0.002

0.09

0.26 (0.05–1.28)

Chemotherapy regimen

  

0.59

  

 FOLFOX

138 (90.2)

11

   

 XELOX

9 (5.9)

10.2

   

 FOLFIRI

4 (2.6)

NA

   

 DCF

2 (1.3)

30

   

PD-L1 CPS (%)

  

0.26

  

 5–9

42 (27.5)

11.7

   

 10–19

47 (30.7)

12

   

 20–49

38 (24.8)

11.2

   

 ≥ %50

26 (17)

8.7

   

NLR

  

0.01

0.55

1.17 (0.68-2)

 < 3.41

75 (49)

14.1

   

 ≥ 3.41

75 (49)

10

   

PLR

  

0.035

0.71

0.88 (0.48–1.64)

 < 169

75 (49)

12.1

   

 ≥ 169

76 (49.6)

10.6

   

SII

  

0.002

0.55

1.2 (0.63–2.36)

 < 1001.2

77 (50.3)

15.6

   

 ≥ 1001.2

76 (49.7)

9.9

   
  1. PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; FOLFOX, folinic acid, fluorouracil, oxaliplatin; XELOX, capecitabine plus oxaliplatin; FOLFIRI, folinic acid, fluorouracil, irinotecan; DCF, Docetaxel, Cysplatin, Fluorouracil; PD-L1: programmed death-ligand 1; CPS, combined positive score; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, Systemic Immune-Inflammation Index.
Back to article page